Glioblastoma (GBM) remains uniformly lethal, and, despite a large accumulation of immune cells in the microenvironment, there is limited anti-tumor immune response, even with newly developed immune checkpoint therapies. To overcome these challenges and enhance the efficacy of immunotherapies, a comprehensive understanding of the immune system in GBM and changes during disease progression is required. Here, we integrated multi-parameter flow cytometry and mass cytometry time of flight (CyTOF) analysis of patient blood to determine changes in the immune system among tumor types and over disease progression. Utilizing multi-parameter flow cytometry analysis in a cohort of over 250 patients with brain tumors ranging from benign to malignant primary and metastatic, we found that GBM patients had a significant elevation in myeloid-derived suppressor cells (MDSCs) in blood, but not immunosuppressive T regulatory cells. We validated these findings in GBM patient tissue and found that increased numbers of MDSCs in recurrent GBM portended poor prognosis. CyTOF analysis of peripheral blood from a cohort of newly diagnosed GBM patients revealed that reduction in MDSC frequency over time is accompanied by a concomitant increase in dendritic cells and natural killer cells. This reduced MDSC profile was present in GBM patients with extended survival and was similar to that of lowgrade glioma (LGG) patients. Our findings provide a rationale for developing strategies to target MDSCs, which are elevated in GBM patients and predict poor prognosis, either by directly targeting or by shifting the immune profile to induce differentiation toward the immune profile of
Introduction
Glioblastoma (GBM) is the most prevalent primary malignant brain tumor and remains uniformly fatal despite aggressive therapies including surgery, radiation, and chemotherapy [1] . Currently, there is great interest in targeting the immune system to promote anti-tumor response as a new means of treating cancers, including GBM [2] [3] [4] . Despite the presence of potential anti-tumor effector cells within the microenvironment, GBM growth persists [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] . One possible explanation for the lack of effective anti-tumor immune response is the presence of a large number of immunosuppressive cells [7, [12] [13] [14] . This is likely due to a number of factors, including immune checkpoint signaling, T cell exhaustion, glucose depletion, hypoxia, and the presence of immunosuppressive cells, such as T regulatory cells, tolerogenic dendritic cells (DCs), and myeloid-derived suppressor cells (MDSCs) [12, 14, 15] . Another factor that contributes to the limited immune response could be that GBM has a low mutational load, which does not allow for the recognition and removal of cancer cells by the immune system [16] . All of these factors combined have led to testing of checkpoint inhibitors in clinical trials, which demonstrated that the antigen-specific T cell responses do not always correlate with tumor regression, suggesting that the immunosuppressive microenvironment limits the potential of T cell activation [17, 18] . While this amount of immunosuppression in GBM appears drastic, it is consistent with the immuneprivileged nature of the brain and may thus be more difficult to reverse than with tumors in other locations [4, 19, 20] .
Given these barriers to the use of immunotherapy approaches, identifying mechanisms of immunosuppression in GBM is an immediate priority. MDSCs are of particular interest given their previously identified role in GBM immunosuppression, immunotherapy response, and cancer progression [12, 13, 15, 21, 22] . A number of contact-dependent and contact-independent pathways have been described for MDSCs, which broadly inhibit T cell proliferation and activation [23] . MDSC production is induced following an inflammatory response to restore homeostasis [24] . However, it has been demonstrated that MDSCs are also increased in most, if not all, cancers in which they have been examined [25] . In addition, it is not surprising that MDSCs are also increased in GBM considering the dire consequences that large-scale inflammation in the brain could cause [26] . This opens up the possibility that while MDSCs could be induced by cancer cells to help evade immune recognition, they may also be recruited by healthy brain cells such as microglia and astrocytes to protect the brain from excessive inflammation [27] . We recently identified an interaction between MDSCs and GBM cancer stem cells via macrophage migration inhibitory factor (MIF) that leads to enhanced MDSC function, increased cytotoxic T cell infiltration, and could be targeted to reduce GBM growth [21] . However, due to the intricate and interconnected nature of the immune system, it is not clear how targeting a single immunosuppressive cell pathway would impact the function of the anti-tumoral immune system.
Taken together this suggests that there is a need to delineate the complex nature of the GBM immune response.
The immune alterations in GBM have primarily been examined with targeted approaches such as immunohistochemical staining and flow cytometry, while RNA sequencing analysis (RNA-seq) remains the only unbiased approach [16, 28, 29] . GBM immunohistochemical analysis has been useful in identifying infiltrating macrophages/monocytes, T regulatory cells, and T cell dysfunction [6, 14, 30] . While immunohistochemical and immunofluorescent staining techniques are becoming more advanced, they fail to provide a general picture of the immune system within GBM [31] . Flow cytometry has similar pitfalls; although flow cytometry has been used successfully to identify immune cell infiltration and dysfunction in GBM, it is limited by the number of fluorescent markers that can be used due to compensation issues and overlap in fluorophore signals [32] .
Finally, RNA-seq studies have been able to profile the immune response in GBM compared to other cancers, but this is a recent development in which the relative abundance of immune cell populations is determined using TCGA pan-cancer data [16] . These RNA-seq studies determined that intra-tumoral MDSCs, T regulatory cells, and effector memory CD4 + T cells are the most prevalent immune cell populations in GBM, with MDSCs enriched in more than 70% of patients with a low mutational burden [16] . While RNA-seq provides new insights into the immune landscape of GBM, these analyses have been performed on bulk tumors and are thus not an ideal way to examine multiple immune cell lineages to determine the composition of the immune microenvironment. An emerging technology with the potential to shed light on the immune microenvironment of many cancers is mass cytometry time of flight (CyTOF) [33] [34] [35] . CyTOF can identify immune cell response and differentiation, which can not be performed by traditional techniques [29] . This approach is currently being used in multiple cancers to examine the immune landscape of tumors in order to identify how to best enhance the anti-tumor immune response [29, 33, 34] . Here, we use a combination of approaches including flow cytometry, immunofluorescence, and CyTOF to identify an immunosuppressive phenotype with increased MDSCs and reduced anti-tumoral response in GBM patients with a poor prognosis compared to low-grade glioma (LGG) patients and GBM patients with a good prognosis.
Results

Flow cytometry analysis identifies increased MDSCs in GBM patients
To quantify immunosuppressive MDSCs in brain tumor patients, peripheral blood mononuclear cells (PBMCs) were isolated from patients undergoing surgical resection (Figure 1A) . The patient cohort for these studies utilized a total of 259 patients, who were subdivided into the categories benign, non-glial malignancy, and glial malignancy (grade I/II, grade III, grade IV (GBM)) ( Figure 1B , with further final diagnoses for each group elaborated on in Supplemental Figure 2 ). When MDSC levels, as determined by the percent of HLA-DR -/low /CD33 + /IBA1 + cells of the total live cells, were compared across groups, we observed that benign samples had a lower percentage of MDSCs compared to non-glial malignancies and grade IV glioma samples but not grade I/II or III glioma samples ( Figure 1C) . Additionally, non-glial malignancies had increased MDSCs compared to grade I/II tumors but not grade III or IV glioma, suggesting that MDSCs may be a possible marker of malignancy in brain tumor patients ( Figure 1C) . A direct comparison among glial malignancies within the categories of grade I/II, III and IV revealed that grade I/II tumors had significantly reduced MDSCs compared to grade IV samples, confirming results found by others (Figure 1 C) [15] . To determine whether other immunosuppressive cell types in circulation are also increased with malignancy, we assessed Tregs as the percentage of Figure 1E ) yielded WHO grade as the most significant predictor of MDSC level (p=0.016). This remained marginally significant in bivariate models that controlled for the potentially confounding clinical variables age (0.016 to 0.076) and chronic steroid use (0.016 to 0.053), i.e. other variables with marginally significant univariate effects. These results demonstrate a relationship between circulating MDSCs and tumor grade but not between T regs and tumor grade.
Immunofluorescence staining of matched primary and recurrent GBM tumors identifies a correlation between M-MDSCs and survival
To validate our observation that circulating MDSCs were associated with increased malignancy, we utilized immunofluorescence analysis of MDSCs in paraffin-embedded matched primary and recurrent tumor samples from 22 GBM patients via antibody staining for CD33, IBA1, and HLA-DR (Supplemental Figure 3, 4) . IBA1 was used in place of CD11b as CD11b has the ability to mark neutrophils and thus granulocytic MDSCs, while IBA1 should appear only on the M-MDSC compartment [36] [37] [38] . Within this cohort, patients were treated with a similar clinical paradigm (radiation and concomitant chemotherapy via the Stupp protocol [1] ). Patients with high and low percentages of MDSCs were identified by the HLA-DR low/negative /IBA1 + /CD33 + area relative to total tumor area using image analysis and grouped based on the MDSC signal in recurrent tumors. To determine whether an increase in MDSCs over the progression of tumors was associated with patient outcome, MDSC-high and MDSC-low groups were compared based on the median MDSC level, and we found that MDSC-high patients had a significantly reduced overall survival compared to MDSC-low patients (Figure 2A) . This was not the case for overall myeloid cells as assessed by CD33 expression, as increased myeloid cell numbers were associated with increased survival (Figure 2B ). Additional analysis of primary and recurrent resection samples for overall survival, time between first and second surgery, survival after the second surgery, and progression-free survival was performed for the correlation between each parameter (spearman r) and also via log-rank test (p-value) ( Figure 2C) . These analyses indicated that MDSC levels at primary resection were not predictive of prognosis but that MDSC levels during recurrence were informative for overall survival, time between first and second surgery, and survival after second surgery (Figure 2C, Supplemental Figure 4 ). These findings demonstrate that an increased infiltration of MDSCs portends poor prognosis, while infiltration of other subtypes of myeloid cells is beneficial.
Longitudinal study of GBM patients using an immune-fingerprinting approach via CyTOF reveals changes over disease progression
To determine how MDSCs and the overall immune system of GBM patients change during disease progression, samples from a cohort of 10 newly diagnosed GBM patients were analyzed via multi-parameter flow cytometry and CyTOF. Blood draws from these patients were obtained during surgery, two weeks post-surgery, and then every two months until the patient left the study or succumbed to disease ( Figure 3A) . Initially, all 10 patients were analyzed by flow cytometry using surface markers of MDSCs and T cells, described above. This analysis did not yield any indicating an increased ability to infiltrate the tumor and suppress the immune system within the tumor microenvironment [41, 42] . A FlowSOM analysis was performed on Patients 2 and 4 to determine the differences in immune response between the two patients, with an in-depth analysis of the markers expressed within each cluster and node, which were generated in an unbiased manner [43] . This analysis randomly clusters immune populations into 10 clusters containing unique nodes (indicated by spheres within the cluster), where the size of the node dictates the size of the population, and the internal pie charts indicate the expression of each marker within the node (Figure 5D) . These results indicate that major differences exist within the anti-tumor immune response of patients with differing prognoses.
CyTOF analysis between two patients with differing prognoses reveals changes in MDSC phenotype and overall immune cell differences
DCs and natural killer (NK) cells are increased in patients with a favorable prognosis
To gain a more in-depth appreciation of the changes in immune cell populations between Patients 2 and 4, 24 individual immune cell populations were manually gated (Supplemental Figure 7) .
We focused on MDSCs and antigen-presenting cells based on our earlier results (Figure 3 and   4 ) and NK cells based on their established role in the anti-tumoral immune response [12, 13, 21, 44, 45] . Compared to baseline, Patient 2 had a substantial increase in DCs at 2 months that was followed by an increase in anti-tumoral NK1 cells (CD45 + , CD66a -, CD3 -, CD19 -, CD20 -, CD14 -, CD11c -, CD56 -, CD16 + ) [46] . Additionally, M-MDSCs were reduced, as was previously identified by the multi-parameter flow cytometry staining, but an additional reduction in immunosuppressive NK2 cells (CD45 + , CD66a -, CD3 -, CD19 -, CD20 -, CD14 -, CD11c -, CD56 + , CD16 -) was discovered using CyTOF ( Figure 6A ) [46] . Patient 4 did not show the same substantial increase in DCs or NK1 cells but instead had increased M-MDSCs and NK2 cells, which indicated an increase in immunouppression compared to Patient 2 (Figure 6A) [47, 48] . The reduction in MDSCs combined with increased DCs indicates the potential differentiation of MDSCs into DCs [49, 50] .
To determine whether environmental conditions were favorable for MDSC differentiation, a 65plex flow cytometry-based cytokine array was applied to serum samples obtained from Patients 2 and 4 at baseline, t1 (2 months) and t2 (last sampling time). This analysis revealed that FMSrelated tyrosine kinase 3 ligand (FLT-3L) and granulocyte-macrophage colony-stimulating factor (GM-CSF), which are able to induce the differentiation of myeloid cells into DCs, were significantly increased in Patient 2 compared to Patient 4 ( Figure 6B ) [51] . Additional patients were examined via cytokine array, which revealed a clear signature of cytokine expression that differed between
LGG and GBM patients (Supplemental Figure 11 ).
CyTOF analysis of LGG patients reveals alterations in DCs and NK cells similar to those of a GBM patient with a favorable prognosis
Based on the distinct immune activation statuses found between two GBM patients (who each had a different survival status and IDH mutation profile), we compared six GBM patients to three
LGG patients at diagnosis using samples on which we performed baseline CyTOF analyses (LGG1= IDH mutant, LGG2 = IDH wild type, LGG3 = IDH wild type). Although MDS revealed no clear difference between patients with GBM and LGG, tSNE analysis showed shifts in immune cell populations between GBM and LGG patients (Supplemental Figure 12) . Further identification of the clusters within the tSNE and a quantification of immune cell changes revealed that the only significantly altered immune cell populations were DCs and NK cells, which were both higher in LGG patients than in GBM patients (Figure 7A, B, Supplemental Figure 13, 14) .
These results were consistent with our longitudinal study finding that a higher frequency of NK cells and DCs associates with a favorable prognosis and suggest that such GBM patients have an immune landscape similar to that of LGG patients.
Discussion
The correlations between peripheral anti-tumoral immune response and tumoral immune response have been of great interest; however, the identification of the peripheral immune status of GBM patients compared to that of patients with other types of brain tumors has not been comprehensively assessed. As the field of tumor immunotherapy progresses, it is vital to determine how the systemic immune response is altered under various tumor diagnoses, as past experiences have revealed that one drug does not work for all patients with the same disease, and it appears that immunotherapies are encountering a similar roadblock [52] . To identify new immunotherapeutic approaches or to enhance the efficacy of existing ones, we must first understand the immune landscape that is altered by the tumor and then ask how the drug of interest impacts that landscape.
Within GBM, patients have a skewed immune system with increased immunosuppression.
However, studies typically focus on only one or two immune cell types of interest and do not examine the immune landscape as a whole or the immune response relative to other brain tumors.
Here, we have developed a focused CyTOF panel to provide an understanding of the immune system as a whole and to predict how immune-modulating therapies may impact the anti-tumoral immune response of patients [53] . This understanding will aide in the investigation of future drugs in an unbiased manner by analyzing immune cell types implicated in immunosuppression and activation within GBM. We hypothesized that MDSCs are increased in GBM patients compared to patients with other types of brain tumors, based on their increased malignancy, and that the systemic immune response to GBM may differ over time among patients based on their prognosis and diagnosis. Our findings support this hypothesis and reveal that GBM patients with a more favorable prognosis exhibit decreased MDSCs and increased DCs, suggesting that MDSC differentiation is associated with an increase in immune activation and thus a decrease in GBM growth.
Through these studies, we found that immunosuppressive MDSCs are elevated in high-grade glial malignancies and in non-glial malignancies with brain metastases, while suppressive T cell populations were not altered as previously reported [28, 54, 55] . This is important as many therapeutic strategies currently under investigation for GBM aim to activate the immune system, as opposed to targeting the immunosuppressive cell types induced by the tumor [3] . While systemic immunosuppression was observed in these studies, we also observed immunosuppression intra-tumorally where MDSCs correlated with overall survival. This observation was made using matched primary and recurrent tumor-resection samples, where elevated levels of CD33 + myeloid cell infiltration correlated with a good prognosis, while infiltration of a specific subtype of myeloid cells, MDSCs, into the tumor microenvironment correlated with poor prognosis. These findings align with the genomic analysis of the immune landscape of IDH wild type and mutant gliomas previously identified [56] . Based on these findings, future studies could be performed to confirm the utility of MDSCs as a biomarker of disease malignancy and progression in brain tumor patients.
To gain an understanding of how patients' immune systems change over time with disease progression, a CyTOF panel focused on 25 immune markers was developed that identified alterations in immune activation status and immunosuppression as a function of time. Specifically, while DCs and CD8 + T cells were increased over time, there was also a corresponding increase in immunosuppressive M-MDSCs and a decrease in B cells. The increase in DCs is of particular interest because it has been shown that DCs from the circulation are more effective at activating an anti-tumoral immune response than resident cells with MHC II such as microglia [57] [58] [59] . This phenomenon of immune recognition without an anti-tumoral immune response has also been observed in clinical trials of immunotherapies [59] . The associations identified between GBM patients and their status of immunosuppression with increasing MDSCs paves the way for future studies to combine anti-MDSC therapy with immune checkpoint therapies to enhance efficacy.
Based on the differences noted between LGG patients and GBM patients by multi-parameter flow cytometry analysis, CyTOF was performed at baseline for LGG and GBM patients. DC and NK cell levels were higher in LGG patients compared to GBM patients, which could indicate that LGG patients are primed for an antigen response prior to surgery and are thus better able to mount an anti-tumor immune response to some degree. On the basis that MDSCs have the ability to differentiate into dendritic cells [23, 50] , the data here suggest that low-grade tumors favor MDSCs maturing into DCs and that high-grade tumors favor MDSCs remaining as MDSCs. Future studies targeting differentiation pathways could enhance the anti-tumoral immune response and increase the efficacy of immune checkpoint therapies.
Materials and Methods
Study design
We sought to determine the relative frequency of MDSCs in GBM patients compared to patients with other primary and secondary malignant and benign brain tumors and, using CyTOF [60] . T regulatory cells were gated as CD3 + , CD4 + , CD25 + , CD127as previously described [61] . CD8 + T cells were gated on CD3 + , CD8 + , CD4 -, which were then determined to be activated by expression of the degranulation marker CD107a [62] .
Immunofluorescence
Fresh tissue biopsies were fixed in 4% neutral buffered formalin and embedded in paraffin. Sample images were collected using systematic uniform random (meander) sampling at 20x magnification with a minimum of five images per tumor. Images were reviewed to ensure that no artifacts or blurring were present. Images were then analyzed to quantify the amount of MDSCs in each tumor using a threshold-based algorithm developed in the Visiopharm software module.
Sections
CD33 was used as an inclusion marker, and the algorithm was designed to identify the entire CD33 + area within the total tumor area. The CD33 + area was then subdivided into IBA1 + and IBA1 -. The CD33 + IBA1 + area was then separated into three areas based on the intensity of HLA-DR staining: 1) CD33 + IBA1 + HLA-DRarea, 2) CD33 + /IBA1 + /HLA-DR LOW area, and 3) CD33 + IBA1 + HLA-DR HIGH area. From these areas, seven area fractions were calculated: 1) the CD33+ area of the total tumor area, 2) the area of MDSCs with no HLA-DR expression within the CD33+ area, Samples were analyzed from six GBM patients at three timepoints for each patient (baseline, 2 months post-recurrence, and final sample collected). Three patients from this group had a good prognosis as denoted by survival >600 days post-resection and were still surviving, while three patients had a poor prognosis as denoted by a survival <600 days. Additionally, three LGG patients were analyzed at baseline for the comparison of baseline samples.
CyTOF analysis
Prior to running CyTOF samples through data analysis, FCS files were normalized between runs using beads and the Nolan lab bead normalizer package [63] . The most current CyTOF data analysis tools were used for data analysis including multi-dimensional analysis with R following methods described by Nowicka et al. [39] . Additionally, FlowSOM analysis of CyTOF data was performed to identify changes in cell populations in an unbiased manner [43] . In a biased approach, CyTOF data was also analyzed using FlowJo software (Tree Star Inc.) as outlined in LGG Pathology Figure 7 p=0.008 p=0.01
